[The results of a 5-year clinical and epidemiological study of the National Program "Chronic tonsillitis"].

Q3 Medicine

Vestnik otorinolaringologii Pub Date : 2024-01-01 DOI:10.17116/otorino20248906128

S A Artyushkin, Yu K Yanov, S V Ryazantsyev, N V Eremina, V K Artyushkina, S A Eremin

{"title":"[The results of a 5-year clinical and epidemiological study of the National Program \"Chronic tonsillitis\"].","authors":"S A Artyushkin, Yu K Yanov, S V Ryazantsyev, N V Eremina, V K Artyushkina, S A Eremin","doi":"10.17116/otorino20248906128","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To study the epidemiological characteristics of chronic tonsillitis (ChT), the need for patients to undergo conservative and surgical treatment, and a comparative assessment of the effectiveness of conservative treatment of patients with chronic tonsillitis using Tonsilotren as monotherapy and in complex treatment. The study involved 999 otorhinolaryngologists from the outpatient network of 20 major Russian cities. The data of 74125 patients diagnosed with ChT were analyzed. A significant predominance of the compensated form of ChT has been established, among the types of decompensation - relapses of acute tonsillitis. The peculiarities of changes in the structure of ChT forms during the period of Sars-CoV-2 coronavirus infection have been established. The expediency of widespread implementation of active measures to identify patients with compensated form of ChT, to perform anti-relapse conservative treatment of ChT using the drug Tonsilotren based on criteria of its effectiveness (IMOS) and tolerability (IMPSS) has been proved.</p>","PeriodicalId":23575,"journal":{"name":"Vestnik otorinolaringologii","volume":"89 6","pages":"28-39"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik otorinolaringologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/otorino20248906128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To study the epidemiological characteristics of chronic tonsillitis (ChT), the need for patients to undergo conservative and surgical treatment, and a comparative assessment of the effectiveness of conservative treatment of patients with chronic tonsillitis using Tonsilotren as monotherapy and in complex treatment. The study involved 999 otorhinolaryngologists from the outpatient network of 20 major Russian cities. The data of 74125 patients diagnosed with ChT were analyzed. A significant predominance of the compensated form of ChT has been established, among the types of decompensation - relapses of acute tonsillitis. The peculiarities of changes in the structure of ChT forms during the period of Sars-CoV-2 coronavirus infection have been established. The expediency of widespread implementation of active measures to identify patients with compensated form of ChT, to perform anti-relapse conservative treatment of ChT using the drug Tonsilotren based on criteria of its effectiveness (IMOS) and tolerability (IMPSS) has been proved.

查看原文本刊更多论文

[国家“慢性扁桃体炎”项目5年临床和流行病学研究结果]。

目的：研究慢性扁桃体炎（ChT）的流行病学特点，患者是否需要保守治疗和手术治疗，比较评价保守治疗慢性扁桃体炎患者单药和复合治疗的效果。这项研究涉及来自俄罗斯20个主要城市门诊网络的999名耳鼻喉科医生。分析了74125例诊断为ChT的患者的资料。在急性扁桃体炎的失代偿复发类型中，已建立了代偿形式的ChT的显著优势。在Sars-CoV-2冠状病毒感染期间，已经确定了ChT形式结构变化的特殊性。广泛实施积极措施来识别代偿型ChT患者，根据其有效性（IMOS）和耐受性（IMPSS）标准使用扁桃体氯胺酮进行抗复发保守治疗的便宜性已被证明。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vestnik otorinolaringologii Medicine-Otorhinolaryngology

CiteScore

0.80

自引率

0.00%

发文量